Replies to post #14014 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Catty, it would all depend on how the deal was structured and if ANIP ponied up more that $2.5 million in further development.

If there is no upfront payment, or a full out sale of Libigel, we may be out of luck by the time the drug hits the market. We would only get 5% of the net revenue ANIP receives and this would run out June 19, 2023.

Basically, if it is deal that was in place when Dr Snabes went to AbbVie, we will probably get the CVR's paid out, as SIMES and other Board members would benefit from the CVR's being paid out. If, on the other hand, the deal was structured after the merger, we are likely out of luck.